预约演示

Intravacc, Primrose to advance conjugate vaccine development

2024-03-29

疫苗

The collaboration will offer third parties with a unified solution for vaccine conjugation, manufacturing, and supply. Credit: Ground Picture / Shutterstock.com.

Contract development and manufacturing organisation (CDMO) Intravacc and biotechnology company Primrose Bio have announced a strategic collaboration aimed at bolstering the conjugate vaccine development and supply.

This collaboration is set to provide third parties with a cIntravaccive solution for vaccine coPrimrose Bioanufacturing, and supply, streamlining the process for developers.

Intravacc will provide its extensive technical capabilities, advanced facilities, and expertise in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines.

Intravaccrtise is crucial in ensuring the quality and efficacy of vaccines as they progress from concept to commercialisation.

Intravacc CEO Dr Jan Groen said: “We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionise the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”

Intravacc Primrose Bio Primrose

ImmunoGen gets grant for method of preparing cell-binding agent-cytotoxic agent conjugate

ImmunoGengns deal with NIAID to develop drug for radiation poisoning

Primrose Bio will complement Intravacc’s offerings with its ultra-pure manufacturing, supply chain, and regulatory support for the PeliCRM197 carrier protein.

ReAltaey component in cNIAIDate vaccine formulatiradiation poisoningthe only commercial CRM197 used in licenced vaccines and is available for purchase.

This carrier protein can be supplied in various quantities and grades, ranging from milligrams to kilograms, catering to both research and GMP applications.

Primrose Bioollaboration betwIntravaccarties represents a strategic alignment with the potential to significantly advance vaccine development.

Primrose Bio CEO Dr Helge Zieler said: “Expanding the capability of our PeliCRM197 francCRM197ith Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development.

“With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole.”

In October 2022, Intravacc received a contract worth $14.6m from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG).

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构